{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T18:02:57Z","timestamp":1789581777750,"version":"build-2803163510"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,2,5]],"date-time":"2021-02-05T00:00:00Z","timestamp":1612483200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2021,2,5]],"date-time":"2021-02-05T00:00:00Z","timestamp":1612483200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"unfunded"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>\n                    <jats:bold>Abstract<\/jats:bold>\n                  <\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>In people living with HIV (PLWH), statins may be disproportionately effective but remain underutilized. A large prospective trial in patients with low to moderate cardiovascular (ASCVD) risk will reveal whether they should be considered in all PLWH. But its effect size may not apply to real-world PLWH with higher ASCVD and mortality risk. Also, the clinical role of non-statin lipid-lowering therapy (LLT) and LLT adherence in this population is unknown.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Comparative multi-level marginal structural model for all-cause mortality examining four time-updated exposure levels to LLT, antihypertensives, and aspirin in a virtual cohort of older PLWH. Incident coronary, cerebrovascular, and overall ASCVD events, serious infections, and new cancer diagnoses served as explanatory outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      In 23,276 HIV-infected US-veterans who were followed for a median of 5.2\u2009years after virologic suppression overall mortality was 33\/1000 patient years: &gt;\u20093 times higher than in the US population. Use of antihypertensives or aspirin was associated with increased mortality. Past LLT use (&gt;\u20091\u2009year ago) had no effect on mortality. LLT exposure in the past year was associated with a reduced hazard ratio (HR) of death: 0.59, 95% confidence interval (CI) 0.51\u20130.69,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.0001 for statin containing LLT and 0.71 (CI: 0.54\u20130.93),\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.03 for statin-free LLT. For consistent LLT use (&gt;\u200911\/12 past months) the HR of death was 0.48 (CI: 0.35\u20130.66) for statin-only LLT, 0.34 (CI: 0.23\u20130.52) for combination LLT, and 0.27 (CI: 0.15\u20130.48) for statin-free LLT (p\u2009&lt;\u20090.0001 for all). The ASCVD risk in these patients was reduced in similar fashion. Use of statin containing LLT was also associated with reduced infection and cancer risk. Multiple contrasting subgroup analyses yielded comparable results. Confounding is unlikely to be a major contributor to our findings.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In PLWH, ongoing LLT use may lead to substantially lower mortality, but consistent long-term adherence may be required to reduce ASCVD risk. Consistent non-statin LLT may be highly effective and should be studied prospectively.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12879-021-05787-4","type":"journal-article","created":{"date-parts":[[2021,2,5]],"date-time":"2021-02-05T08:08:27Z","timestamp":1612512507000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Consistent use of lipid lowering therapy in HIV infection is associated with low mortality"],"prefix":"10.1186","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4026-9154","authenticated-orcid":false,"given":"Henning","family":"Drechsler","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Colby","family":"Ayers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Cutrell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reuben","family":"Arasaratnam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roger","family":"Bedimo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,2,5]]},"reference":[{"issue":"2","key":"5787_CR1","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1097\/QAI.0000000000000825","volume":"71","author":"RA Legarth","year":"2016","unstructured":"Legarth RA, Ahlstr\u00f6m MG, Kronborg G, Larsen CS, Pedersen C, Pedersen G, Mohey R, Gerstoft J, Obel N. Long-term mortality in HIV-infected individuals 50 years or older: a Nationwide, population-based cohort study. J Acquir Immune Defic Syndr. 2016;71(2):213\u20138.","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"6","key":"5787_CR2","doi-asserted-by":"publisher","first-page":"e207954","DOI":"10.1001\/jamanetworkopen.2020.7954","volume":"3","author":"JL Marcus","year":"2020","unstructured":"Marcus JL, Leyden WA, Alexeeff SE, Anderson AN, Hechter RC, Hu H, Lam JO, Towner WJ, Yuan Q, Horberg MA, et al. Comparison of overall and comorbidity-free life expectancy between insured adults with and without HIV infection, 2000-2016. JAMA Netw Open. 2020;3(6):e207954.","journal-title":"JAMA Netw Open"},{"issue":"22","key":"5787_CR3","doi-asserted-by":"publisher","first-page":"2283","DOI":"10.1056\/NEJMoa062360","volume":"355","author":"Strategies for Management of Antiretroviral Therapy Study G","year":"2006","unstructured":"Strategies for Management of Antiretroviral Therapy Study G. El-Sadr WM, Lundgren J, Neaton JD, Gordin F, Abrams D, Arduino RC, Babiker a, Burman W, Clumeck N et al: CD4+ count-guided interruption of antiretroviral treatment. N Engl J Med. 2006;355(22):2283\u201396.","journal-title":"N Engl J Med"},{"issue":"8","key":"5787_CR4","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1001\/jamainternmed.2013.3728","volume":"173","author":"MS Freiberg","year":"2013","unstructured":"Freiberg MS, Chang C-CH, Kuller LH, Skanderson M, Lowy E, Kraemer KL, Butt AA, Bidwell Goetz M, Leaf D, Oursler KA, et al. HIV infection and the risk of acute myocardial infarction. JAMA Intern Med. 2013;173(8):614\u201322.","journal-title":"JAMA Intern Med"},{"key":"5787_CR5","first-page":"11","volume":"11","author":"RJ Bedimo","year":"2020","unstructured":"Bedimo RJ, Park LS, Shebl F, Sigel K, Rentsch CT, Crothers K, Rodriguez-Barradas MC, Goetz MB, Butt AA, Brown ST, et al. Statin exposure and risk of cancer in people with and without HIV infection. Aids. 2020;11:11.","journal-title":"Aids"},{"key":"5787_CR6","doi-asserted-by":"publisher","first-page":"a3172","DOI":"10.1136\/bmj.a3172","volume":"338","author":"SG Deeks","year":"2009","unstructured":"Deeks SG, Phillips AN. HIV infection, antiretroviral treatment, ageing, and non-AIDS related morbidity. BMJ. 2009;338:a3172.","journal-title":"BMJ"},{"issue":"1","key":"5787_CR7","doi-asserted-by":"publisher","first-page":"e35","DOI":"10.1016\/S2468-2667(16)30020-2","volume":"2","author":"S Croxford","year":"2017","unstructured":"Croxford S, Kitching A, Desai S, Kall M, Edelstein M, Skingsley A, Burns F, Copas A, Brown AE, Sullivan AK, et al. Mortality and causes of death in people diagnosed with HIV in the era of highly active antiretroviral therapy compared with the general population: an analysis of a national observational cohort. Lancet Public Health. 2017;2(1):e35\u201346.","journal-title":"Lancet Public Health"},{"issue":"2","key":"5787_CR8","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1089\/aid.2016.0222","volume":"33","author":"F Goehringer","year":"2017","unstructured":"Goehringer F, Bonnet F, Salmon D, Cacoub P, Paye A, Chene G, Morlat P, May T. Causes of death in HIV-infected individuals with Immunovirologic success in a National Prospective Survey. AIDS Res Human Retroviruses. 2017;33(2):187\u201393.","journal-title":"AIDS Res Human Retroviruses"},{"issue":"7","key":"5787_CR9","first-page":"938","volume":"11","author":"AK Sullivan","year":"1997","unstructured":"Sullivan AK, Nelson MR. Marked hyperlipidaemia on ritonavir therapy. AIDS. 1997;11(7):938\u20139.","journal-title":"AIDS"},{"issue":"9112","key":"5787_CR10","doi-asserted-by":"publisher","first-page":"1328","DOI":"10.1016\/S0140-6736(05)79053-X","volume":"351","author":"K Henry","year":"1998","unstructured":"Henry K, Melroe H, Huebsch J, Hermundson J, Levine C, Swensen L, Daley J. Severe premature coronary artery disease with protease inhibitors. Lancet. 1998;351(9112):1328.","journal-title":"Lancet"},{"issue":"22","key":"5787_CR11","doi-asserted-by":"publisher","first-page":"2978","DOI":"10.1001\/jama.289.22.2978","volume":"289","author":"SA Riddler","year":"2003","unstructured":"Riddler SA, Smit E, Cole SR, Li R, Chmiel JS, Dobs A, Palella F, Visscher B, Evans R, Kingsley LA. Impact of HIV infection and HAART on serum lipids in men. Jama. 2003;289(22):2978\u201382.","journal-title":"Jama"},{"issue":"16","key":"5787_CR12","doi-asserted-by":"publisher","first-page":"2469","DOI":"10.1097\/QAD.0000000000001219","volume":"30","author":"NT Oliver","year":"2016","unstructured":"Oliver NT, Hartman CM, Kramer JR, Chiao EY. Statin drugs decrease progression to cirrhosis in HIV\/hepatitis C virus coinfected individuals. AIDS. 2016;30(16):2469\u201376.","journal-title":"AIDS"},{"issue":"3","key":"5787_CR13","doi-asserted-by":"publisher","first-page":"e0172175","DOI":"10.1371\/journal.pone.0172175","volume":"12","author":"H Drechsler","year":"2017","unstructured":"Drechsler H, Ayers C, Cutrell J, Maalouf N, Tebas P, Bedimo R. Current use of statins reduces risk of HIV rebound on suppressive HAART. PLoS One. 2017;12(3):e0172175.","journal-title":"PLoS One"},{"issue":"14","key":"5787_CR14","doi-asserted-by":"publisher","first-page":"1719","DOI":"10.1080\/14656566.2019.1636033","volume":"20","author":"A Gebhardt","year":"2019","unstructured":"Gebhardt A, Fichtenbaum CJ. Current pharmacotherapy for the treatment of dyslipidemia associated with HIV infection. Expert Opin Pharmacother. 2019;20(14):1719\u201329.","journal-title":"Expert Opin Pharmacother"},{"key":"5787_CR15","unstructured":"Knobel H, Fratchez V, Montero M. The use of statins was associated with reduced mortality in HIV-infected patients [Abstract PE12\/7]. In: 14th European AIDS Conference October 16\u201319. Brussels; 2013."},{"issue":"7","key":"5787_CR16","doi-asserted-by":"publisher","first-page":"e21843","DOI":"10.1371\/journal.pone.0021843","volume":"6","author":"RD Moore","year":"2011","unstructured":"Moore RD, Bartlett JG, Gallant JE. Association between use of HMG CoA reductase inhibitors and mortality in HIV-infected patients. PLoS One. 2011;6(7):e21843.","journal-title":"PLoS One"},{"issue":"10","key":"5787_CR17","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.1093\/cid\/cit053","volume":"56","author":"ET Overton","year":"2013","unstructured":"Overton ET, Kitch D, Benson CA, Hunt PW, Stein JH, Smurzynski M, Ribaudo HJ, Tebas P. Effect of statin therapy in reducing the risk of serious non-AIDS-defining events and nonaccidental death. Clin Infect Dis. 2013;56(10):1471\u20139.","journal-title":"Clin Infect Dis"},{"issue":"6","key":"5787_CR18","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1089\/apc.2014.0309","volume":"29","author":"M Krsak","year":"2015","unstructured":"Krsak M, Kent DM, Terrin N, Holcroft C, Skinner SC, Wanke C. Myocardial infarction, stroke, and mortality in cART-treated HIV patients on statins. AIDS Patient Care Stds. 2015;29(6):307\u201313.","journal-title":"AIDS Patient Care Stds"},{"issue":"1","key":"5787_CR19","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1186\/s12879-018-3162-1","volume":"18","author":"OA Uthman","year":"2018","unstructured":"Uthman OA, Nduka C, Watson SI, Mills EJ, Kengne AP, Jaffar SS, Clarke A, Moradi T, Ekstrom AM, Lilford R. Statin use and all-cause mortality in people living with HIV: a systematic review and meta-analysis. BMC Infect Dis. 2018;18(1):258.","journal-title":"BMC Infect Dis"},{"issue":"10","key":"5787_CR20","doi-asserted-by":"publisher","first-page":"1601","DOI":"10.1038\/s41591-019-0597-x","volume":"25","author":"BA Dickerman","year":"2019","unstructured":"Dickerman BA, Garc\u00eda-Alb\u00e9niz X, Logan RW, Denaxas S, Hern\u00e1n MA. Avoidable flaws in observational analyses: an application to statins and cancer. Nat Med. 2019;25(10):1601\u20136.","journal-title":"Nat Med"},{"issue":"1","key":"5787_CR21","doi-asserted-by":"publisher","first-page":"e26","DOI":"10.1097\/QAI.0000000000001454","volume":"76","author":"SG Kelly","year":"2017","unstructured":"Kelly SG, Krueger KM, Grant JL, Penugonda S, Feinstein MJ, Taiwo BO, Achenbach CJ. Statin prescribing practices in the comprehensive care for HIV-infected patients. J Acquired Immune Deficiency Syndr. 2017;76(1):e26\u20139.","journal-title":"J Acquired Immune Deficiency Syndr"},{"issue":"25_suppl_2","key":"5787_CR22","doi-asserted-by":"publisher","first-page":"S49","DOI":"10.1161\/01.cir.0000437741.48606.98","volume":"129","author":"DC Goff","year":"2014","unstructured":"Goff DC, Lloyd-Jones DM, Bennett G, Coady S, D\u2019Agostino RB, Gibbons R, Greenland P, Lackland DT, Levy D, O\u2019Donnell CJ, et al. 2013 ACC\/AHA guideline on the assessment of cardiovascular risk. Circulation. 2014;129(25_suppl_2):S49\u201373.","journal-title":"Circulation"},{"key":"5787_CR23","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.ahj.2018.12.016","volume":"212","author":"SK Grinspoon","year":"2019","unstructured":"Grinspoon SK, Fitch KV, Overton ET, Fichtenbaum CJ, Zanni MV, Aberg JA, Malvestutto C, Lu MT, Currier JS, Sponseller CA, et al. Rationale and design of the randomized trial to prevent vascular events in HIV (REPRIEVE). Am Heart J. 2019;212:23\u201335.","journal-title":"Am Heart J"},{"issue":"Supplement_1","key":"5787_CR24","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1093\/infdis\/jiaa098","volume":"222","author":"SK Grinspoon","year":"2020","unstructured":"Grinspoon SK, Douglas PS, Hoffmann U, Ribaudo HJ. Leveraging a Landmark Trial of Primary Cardiovascular Disease Prevention in Human Immunodeficiency Virus: Introduction From the REPRIEVE Coprincipal Investigators. J Infect Dis. 2020;222(Supplement_1):S1\u20137.","journal-title":"J Infect Dis"},{"issue":"Suppl 1","key":"5787_CR25","doi-asserted-by":"publisher","first-page":"S12","DOI":"10.1016\/S0895-4356(01)00442-5","volume":"54","author":"L Backus","year":"2001","unstructured":"Backus L, Mole L, Chang S, Deyton L. The immunology case registry. J Clin Epidemiol. 2001;54(Suppl 1):S12\u20135.","journal-title":"J Clin Epidemiol"},{"issue":"7","key":"5787_CR26","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1016\/S1047-2797(01)00285-X","volume":"12","author":"DC Cowper","year":"2002","unstructured":"Cowper DC, Kubal JD, Maynard C, Hynes DM. A primer and comparative review of major US mortality databases. Ann Epidemiol. 2002;12(7):462\u20138.","journal-title":"Ann Epidemiol"},{"issue":"5","key":"5787_CR27","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1177\/1060028016634106","volume":"50","author":"I Arnet","year":"2016","unstructured":"Arnet I, Kooij MJ, Messerli M, Hersberger KE, Heerdink ER, Bouvy M. Proposal of standardization to assess adherence with medication records: methodology matters. Ann Pharmacother. 2016;50(5):360\u20138.","journal-title":"Ann Pharmacother"},{"issue":"1","key":"5787_CR28","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1093\/rheumatology\/kez320","volume":"59","author":"T St\u00fcrmer","year":"2019","unstructured":"St\u00fcrmer T, Wang T, Golightly YM, Keil A, Lund JL, Jonsson Funk M. Methodological considerations when analysing and interpreting real-world data. Rheumatology. 2019;59(1):14\u201325.","journal-title":"Rheumatology"},{"issue":"1","key":"5787_CR29","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1111\/j.2517-6161.1995.tb02031.x","volume":"57","author":"Y Benjamini","year":"1995","unstructured":"Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc Ser B Methodol. 1995;57(1):289\u2013300.","journal-title":"J R Stat Soc Ser B Methodol"},{"key":"5787_CR30","unstructured":"Therneau T: A Package for Survival Analysis in S_. version 2.38. In.: http:\/\/CRAN.R-project.org\/package=survival; 2015."},{"key":"5787_CR31","unstructured":"Detailed Tables for the National Vital Statistics Report (NVSR) \u201cDeaths: Final Data for 2013 [http:\/\/www.cdc.gov\/nchs\/data_access\/Vitalstatsonline.htm]."},{"issue":"28","key":"5787_CR32","doi-asserted-by":"publisher","first-page":"3661","DOI":"10.1002\/sim.6607","volume":"34","author":"PC Austin","year":"2015","unstructured":"Austin PC, Stuart EA. Moving towards best practice when using inverse probability of treatment weighting (IPTW) using the propensity score to estimate causal treatment effects in observational studies. Stat Med. 2015;34(28):3661\u201379.","journal-title":"Stat Med"},{"issue":"8","key":"5787_CR33","doi-asserted-by":"publisher","first-page":"3636","DOI":"10.1177\/0300060519856137","volume":"47","author":"CY Cheng","year":"2019","unstructured":"Cheng CY, Kung CT, Chen FC, Cheng HH, Tsai TC, Hsiao SY, Su CM. Impact of prior statin use on mortality in patients with type 2 diabetes mellitus and bloodstream infection. J Int Med Res. 2019;47(8):3636\u201347.","journal-title":"J Int Med Res"},{"issue":"10","key":"5787_CR34","doi-asserted-by":"publisher","first-page":"1737","DOI":"10.1136\/annrheumdis-2017-211253","volume":"76","author":"A Oza","year":"2017","unstructured":"Oza A, Lu N, Schoenfeld SR, Fisher MC, Dubreuil M, Rai SK, Zhang Y, Choi HK. Survival benefit of statin use in ankylosing spondylitis: a general population-based cohort study. Ann Rheum Dis. 2017;76(10):1737\u201342.","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"5787_CR35","doi-asserted-by":"publisher","first-page":"1514","DOI":"10.1002\/lt.25613","volume":"25","author":"SS Patel","year":"2019","unstructured":"Patel SS, Rodriguez VA, Siddiqui MB, Faridnia M, Lin F-P, Chandrakumaran A, Laurenzano J, Clinton J, Kowlgi GN, Kirkman D, et al. The impact of coronary artery disease and statins on survival after liver transplantation. Liver Transplantation. 2019;25(10):1514\u201323.","journal-title":"Liver Transplantation"},{"issue":"1","key":"5787_CR36","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1186\/s12944-019-1053-0","volume":"18","author":"K An","year":"2019","unstructured":"An K, Huang R, Tian S, Guo D, Wang J, Lin H, Wang S. Statins significantly reduce mortality in patients receiving clopidogrel without affecting platelet activation and aggregation: a systematic review and meta-analysis. Lipids Health Dis. 2019;18(1):121\u201331.","journal-title":"Lipids Health Dis."},{"issue":"6","key":"5787_CR37","doi-asserted-by":"publisher","first-page":"874","DOI":"10.1016\/j.euf.2017.03.015","volume":"4","author":"G Di Lorenzo","year":"2018","unstructured":"Di Lorenzo G, Sonpavde G, Pond G, Lucarelli G, Rossetti S, Facchini G, Scagliarini S, Carteni G, Federico P, Daniele B, et al. Statin use and survival in patients with metastatic castration-resistant prostate Cancer treated with Abiraterone acetate. Eur Urol Focus. 2018;4(6):874\u20139.","journal-title":"Eur Urol Focus"},{"key":"5787_CR38","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1016\/j.jocn.2019.07.045","volume":"69","author":"HC Lin","year":"2019","unstructured":"Lin HC, Tsai WC, Lin JR, Chang WN, Huang CC, Wang HC, Kung CT, Su CM, Su YJ, Lin WC, et al. Adjunctive statin therapy reduces intracranial hemorrhage and 1-year mortality in patients with atrial fibrillation after acute ischemic stroke: a population-based epidemiological study from Taiwan. J Clin Neurosci. 2019;69:224\u20139.","journal-title":"J Clin Neurosci"},{"issue":"1","key":"5787_CR39","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1186\/s12944-019-1011-x","volume":"18","author":"J Rusnak","year":"2019","unstructured":"Rusnak J, Behnes M, Schupp T, Lang S, Reiser L, Taton G, Bollow A, Reichelt T, Ellguth D, Engelke N, et al. Statin therapy is associated with improved survival in patients with ventricular tachyarrhythmias. Lipids Health Dis. 2019;18(1):119\u201329.","journal-title":"Lipids Health Dis."},{"issue":"1","key":"5787_CR40","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1001\/jama.2020.7848","volume":"324","author":"AR Orkaby","year":"2020","unstructured":"Orkaby AR, Driver JA, Ho Y-L, Lu B, Costa L, Honerlaw J, Galloway A, Vassy JL, Forman DE, Gaziano JM, et al. Association of Statin use with all-Cause and Cardiovascular Mortality in US veterans 75 years and older. Jama. 2020;324(1):68\u201378.","journal-title":"Jama"},{"issue":"1","key":"5787_CR41","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa1812792","volume":"380","author":"DL Bhatt","year":"2018","unstructured":"Bhatt DL, Steg PG, Miller M, Brinton EA, Jacobson TA, Ketchum SB, Doyle RT, Juliano RA, Jiao L, Granowitz C, et al. Cardiovascular risk reduction with Icosapent ethyl for hypertriglyceridemia. N Engl J Med. 2018;380(1):11\u201322.","journal-title":"N Engl J Med"},{"issue":"2","key":"5787_CR42","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1161\/CIRCULATIONAHA.118.038840","volume":"140","author":"PG Steg","year":"2019","unstructured":"Steg PG, Szarek M, Bhatt DL, Bittner VA, Br\u00e9geault M-F, Dalby AJ, Diaz R, Edelberg JM, Goodman SG, Hanotin C, et al. Effect of Alirocumab on mortality after acute coronary syndromes. Circulation. 2019;140(2):103\u201312.","journal-title":"Circulation"},{"issue":"4","key":"5787_CR43","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1097\/HCO.0000000000000627","volume":"34","author":"WG Simpson","year":"2019","unstructured":"Simpson WG. Biomarker variability and cardiovascular disease residual risk. Curr Opin Cardiol. 2019;34(4):413\u20137.","journal-title":"Curr Opin Cardiol"},{"issue":"48","key":"5787_CR44","doi-asserted-by":"publisher","first-page":"3560","DOI":"10.1093\/eurheartj\/ehx585","volume":"38","author":"MK Kim","year":"2017","unstructured":"Kim MK, Han K, Kim H-S, Park Y-M, Kwon H-S, Yoon K-H, Lee S-H. Cholesterol variability and the risk of mortality, myocardial infarction, and stroke: a nationwide population-based study. Eur Heart J. 2017;38(48):3560\u20136.","journal-title":"Eur Heart J"},{"issue":"Suppl 1","key":"5787_CR45","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1002\/pds.4890","volume":"29","author":"M Eberg","year":"2020","unstructured":"Eberg M, Platt RW, Reynier P, Filion KB. Estimation of high-dimensional propensity scores with multiple exposure levels. Pharmacoepidemiol Drug Saf. 2020;29(Suppl 1):53\u201360.","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"4","key":"5787_CR46","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1093\/aje\/kwm324","volume":"167","author":"S Suissa","year":"2008","unstructured":"Suissa S. Immortal time bias in pharmaco-epidemiology. Am J Epidemiol. 2008;167(4):492\u20139.","journal-title":"Am J Epidemiol"},{"issue":"4","key":"5787_CR47","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1016\/j.jval.2010.10.033","volume":"14","author":"AR Patrick","year":"2011","unstructured":"Patrick AR, Shrank WH, Glynn RJ, Solomon DH, Dormuth CR, Avorn J, Cadarette SM, Mogun H, Brookhart MA. The association between statin use and outcomes potentially attributable to an unhealthy lifestyle in older adults. Value Health. 2011;14(4):513\u201320.","journal-title":"Value Health"},{"issue":"15","key":"5787_CR48","doi-asserted-by":"publisher","first-page":"2051","DOI":"10.1161\/CIRCULATIONAHA.108.824151","volume":"119","author":"CR Dormuth","year":"2009","unstructured":"Dormuth CR, Patrick AR, Shrank WH, Wright JM, Glynn RJ, Sutherland J, Brookhart MA. Statin adherence and risk of accidents: a cautionary tale. Circulation. 2009;119(15):2051\u20137.","journal-title":"Circulation"},{"issue":"5","key":"5787_CR49","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1097\/00001648-200009000-00011","volume":"11","author":"JM Robins","year":"2000","unstructured":"Robins JM, Hernan MA, Brumback B. Marginal structural models and causal inference in epidemiology. Epidemiology (Cambridge, Mass). 2000;11(5):550\u201360.","journal-title":"Epidemiology (Cambridge, Mass)"},{"issue":"1","key":"5787_CR50","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.jclinepi.2009.03.001","volume":"63","author":"JL Bosco","year":"2010","unstructured":"Bosco JL, Silliman RA, Thwin SS, Geiger AM, Buist DS, Prout MN, Yood MU, Haque R, Wei F, Lash TL. A most stubborn bias: no adjustment method fully resolves confounding by indication in observational studies. J Clin Epidemiol. 2010;63(1):64\u201374.","journal-title":"J Clin Epidemiol"},{"issue":"15","key":"5787_CR51","doi-asserted-by":"publisher","first-page":"2387","DOI":"10.1097\/QAD.0000000000002350","volume":"33","author":"A Milinkovic","year":"2019","unstructured":"Milinkovic A, Berger F, Arenas-Pinto A, Mauss S. Reversible effect on lipids by switching from tenofovir disoproxil fumarate to tenofovir alafenamide and back. AIDS. 2019;33(15):2387\u201391.","journal-title":"AIDS"},{"issue":"11","key":"5787_CR52","doi-asserted-by":"publisher","first-page":"1781","DOI":"10.1097\/QAD.0b013e32833ad8b4","volume":"24","author":"M Tungsiripat","year":"2010","unstructured":"Tungsiripat M, Kitch D, Glesby MJ, Gupta SK, Mellors JW, Moran L, Jones L, Alston-Smith B, Rooney JF, Aberg JA. A pilot study to determine the impact on dyslipidemia of adding tenofovir to stable background antiretroviral therapy: ACTG 5206. AIDS. 2010;24(11):1781\u20134.","journal-title":"AIDS"},{"key":"5787_CR53","first-page":"295","volume":"58","author":"AB Hill","year":"1965","unstructured":"Hill AB. The environment and disease: association or causation? Proc R Soc Med. 1965;58:295\u2013300.","journal-title":"Proc R Soc Med"},{"issue":"19","key":"5787_CR54","doi-asserted-by":"publisher","first-page":"2486","DOI":"10.1001\/jama.285.19.2486","volume":"285","author":"Expert Panel on Detection E","year":"2001","unstructured":"Expert Panel on Detection E. Treatment of high blood cholesterol in a: executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III). Jama. 2001;285(19):2486\u201397.","journal-title":"Jama"},{"issue":"2","key":"5787_CR55","doi-asserted-by":"publisher","first-page":"e98","DOI":"10.1161\/CIR.0000000000000695","volume":"140","author":"MJ Feinstein","year":"2019","unstructured":"Feinstein MJ, Hsue PY, Benjamin LA, Bloomfield GS, Currier JS, Freiberg MS, Grinspoon SK, Levin J, Longenecker CT, Post WS. Characteristics, prevention, and Management of Cardiovascular Disease in people living with HIV: a scientific statement from the American Heart Association. Circulation. 2019;140(2):e98\u2013e124.","journal-title":"Circulation"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-021-05787-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12879-021-05787-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-021-05787-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,23]],"date-time":"2024-08-23T13:31:50Z","timestamp":1724419910000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/s12879-021-05787-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,5]]},"references-count":55,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["5787"],"URL":"https:\/\/doi.org\/10.1186\/s12879-021-05787-4","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-122948\/v1","asserted-by":"object"}],"has-review":[{"id-type":"doi","id":"10.3410\/f.739504533.793583908","asserted-by":"object"}]},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,5]]},"assertion":[{"value":"26 November 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 January 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 February 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The VA North Texas Health Care System Institutional Review Board approved this study. Consent was waived because of minimal risk to participants and the nature of the study (de-identified data).","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"N\/A","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"150"}}